You are here: Welcome to the MPKB » Welcome to the MPKB » Science behind Marshall Paradigm » Science behind olmesartan (Benicar) » Safety of olmesartan (Benicar)
Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision		Previous revision
Next revisionBoth sides next revision
home:protocol:olmesartan:safety [12.29.2018] – [Notes and comments] sallieqhome:protocol:olmesartan:safety [07.19.2019] – [Safety of olmesartan (Benicar)] sallieq
Line 1: Line 1:
    
 ====== Safety of olmesartan (Benicar) ====== ====== Safety of olmesartan (Benicar) ======
 +
 +<relatedarticle> [[home:diseases:celiac#recent_research|Recent research into Celiac disease]] </article>
  
 Some patients and healthcare providers have expressed concerns about the safety of higher than typical [[home:mp:olmesartan:dosing|doses of olmesartan (Benicar)]]. Some patients and healthcare providers have expressed concerns about the safety of higher than typical [[home:mp:olmesartan:dosing|doses of olmesartan (Benicar)]].
Line 35: Line 37:
  
 The [[http://www.benicar.com/pdf/prescribing_information.pdf|label for olmesartan]] states that the drug is well-tolerated. Adverse events were similar to those experienced by the placebo group – a group of patients who were not given the drug at all. Adverse events were generally “mild, transient and not related to dose.” The frequency of adverse events also had no relationship to the dose of olmesartan. The [[http://www.benicar.com/pdf/prescribing_information.pdf|label for olmesartan]] states that the drug is well-tolerated. Adverse events were similar to those experienced by the placebo group – a group of patients who were not given the drug at all. Adverse events were generally “mild, transient and not related to dose.” The frequency of adverse events also had no relationship to the dose of olmesartan.
 +
 +From a MPStudySite topic 
 +<blockquote>  a Member recently reported "taking a whole days worth of Benicar into my mouth and they were down before I could stop them.  Had forgotten I hadn't just put the one 6 a.m. dose in the container....  no adverse effects.</blockquote>
  
  
Line 119: Line 124:
  
 [[http://doi.org/10.5761/atcs.oa.11.01691|angiotensin II and aldosterone are decreased in a change-over from candesartan to olmesartan]] [[http://doi.org/10.5761/atcs.oa.11.01691|angiotensin II and aldosterone are decreased in a change-over from candesartan to olmesartan]]
 +
 +With the halt of reimbursement of olmesartan, there was a decrease in the prescription of ARB in France. When olmersartan was replaced by another ARB, a worse blood pressure control was observed in treated hypertensive patients.  (({{pubmed>long:29807620 }}))
 +
 +
 +==== Enteropathy ====
 +
 +The incidence of this adverse drug reaction is not entirely clear, although it is thought to be rare. 
 +(({{pubmed>long:26997446}}))
 +
 +
 +Seven cases (2.8%) reported recurrence of symptoms after restarting olmesartan (({{pubmed>long:31217979}}))
 +
 +Although enteropathy is rare, clinicians should remain vigilant of this potential adverse event even years after medication initiation. 
 +(({{pubmed>long:31217979}}))
 +
 +results suggest that SMEEDS formulation improves dissolution and oral bioavailability of OM while reducing adverse effects (celiac-like enteropathy or diarrhea ). (({{pubmed>long:30986085}}))
 +
 +==== Collagenous enteritis, a genetic problem? ====
 +
 +Collagenous enteritis is an uncommon small intestinal injury pattern with unclear pathogenesis. 
 +
 +All subjects with biopsy-proven collagenous enteritis diagnosed between 2002 and 2015 were identified from 2 tertiary care medical centers. Human leukocyte antigen (HLA)-DQ genotyping was performed by polymerase chain reaction on archived tissue. Celiac disease serology, past medical history, medications, smoking history, demographics, histology, clinical management, and follow-up were recorded. A total of 32 subjects were included. In contrast to celiac disease, subjects with collagenous enteritis were mostly elderly (median age at diagnosis, 69 y; range, 33 to 84 y). Seventy percent of collagenous enteritis subjects harbored celiac disease susceptibility alleles HLA-DQ2/DQ8; however, only 1 subject had elevated serum levels of celiac disease-associated autoantibodies while on a gluten-containing diet. Furthermore, 56% of subjects were taking nonsteroidal anti-inflammatory drugs, 36% proton-pump inhibitors, 28% statins, and 32% olmesartan at the time of diagnosis. Discontinuation of olmesartan and treatments with steroids and/or gluten-free diet resulted in symptomatic and histologic improvement. (({{pubmed>long:29324472 }}))
 +
 +Olmesartan was not associated with intestinal malabsorption or significant body weight loss in the general Korean population.  (({{pubmed>long:29172402}}))
  
 ===== Notes and comments ===== ===== Notes and comments =====
home/protocol/olmesartan/safety.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.